Development of a saRNA nano-vaccine for Prostate Cancer


   School of Pharmacy

This project is no longer listed on FindAPhD.com and may not be available.

Click here to search FindAPhD.com for PhD studentship opportunities
  Prof Helen McCarthy, Dr J Coulter  Applications accepted all year round  Self-Funded PhD Students Only

About the Project

Treatment options for castrate resistant prostate cancer (CRPC) are primarily palliative. Clinically relevant immune-cell stimulated tumour-associated antigens (TAAs) have been identified that negatively correlate with treatment outcome. Nucleic acid vaccination holds tremendous potential, possessing both prophylactic and therapeutic application. Of these, RNA vaccines are much more potent than DNA vaccines, with smaller quantities stimulating greater immune responses. RNA-based vaccines have the advantage of low manufacturing cost, inducing B and T cell responses, high specificity, high stability, absence of anti-vector immunity, lower reactogenicity and lacking the ability to be integrated into the host cells genome. The main disadvantage of using RNA as a vaccine is the requirement for cytoplasmic delivery to host cells and generating a strong long-lasting immunity. This project is designed to overcome these limitations by using our patented non-immunogenic drug delivery system (RALA) to improve cytoplasmic delivery and to enhance the immune response by delivering both saRNA encoding TAAs for CRPC and B cell activating CpG adjuvants. The end-point will determination of a candidate RALA/saRNA vaccine that will elicit both prophylactic and therapeutic immune responses to CRPC tumours that can then be further developed towards the clinic.

This projects forms part of an exciting collaborative partnership between Professor McCarthy, a nucleic acids drug delivery expert and CEO of Phion Therapeutics and Dr Jonathan Coulter, a prostate cancer expert in translational medicine. The student will benefit from training in both an academic and industry setting including placements in Phion Therapeutics. The project workplan encompasses a broad range of molecular biology, physiochemical and in vivo techniques providing the student with an excellent training environment and key transferable skills for future development.

Funding Notes

Applicants should have a 1st or 2.1 honours degree (or equivalent) in a relevant subject. Relevant subjects include Pharmacy, Molecular Biology, Pharmaceutical Sciences, Biochemistry, Biological/Biomedical Sciences, Chemistry, Engineering, or a closely related discipline. Students who have a 2.2 honours degree and a Master’s degree may also be considered, but the School reserves the right to shortlist for interview only those applicants who have demonstrated high academic attainment to date.

References

http://www.qub.ac.uk/schools/SchoolofPharmacy/Research/PostgraduatePositions/

http://www.qub.ac.uk/schools/SchoolofPharmacy/Research/

https://www.qub.ac.uk/schools/SchoolofPharmacy/Research/ResearchThemes/
NanomedicineandBiotherapeutics/

https://www.qub.ac.uk/schools/SchoolofPharmacy/Research/find-a-phd-supervisor/professor-helen-mccarthy.html

https://www.qub.ac.uk/schools/SchoolofPharmacy/Research/find-a-phd-supervisor/dr-jonathan-coulter.html

www.phiontx.co.uk
Search Suggestions
Search suggestions

Based on your current searches we recommend the following search filters.

PhD saved successfully
View saved PhDs